MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 129057 | Name: KDX1381

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KDX1381K is a bivalent CK2α inhibitor with low-nanomolar potency and high selectivity, confirmed by cocrystal structures. In mice, KDX1381 suppressed CK2-driven tumor growth as a monotherapy and enhanced therapeutic efficacy when combined with vascular endothelial growth factor receptor (VEGFR) inhibitors or DNA-damaging agents in hepatocellular carcinoma and glioma models.

Chemical Structure

KDX1381
KDX1381
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 129057

Name: KDX1381

CAS#: N/A

Chemical Formula: C32H32F2N6O4S

Exact Mass: 634.2200

Molecular Weight: 634.70

Elemental Analysis: C, 60.56; H, 5.08; F, 5.99; N, 13.24; O, 10.08; S, 5.05

Price and Availability

Related CAS #
No Data
Synonym
KDX1381; KDX 1381; KDX-1381
IUPAC/Chemical Name
N-(2-(4-((4-(2-acetyl-5-fluoro-1H-indol-3-yl)-1H-1,2,3-triazol-1-yl)methyl)piperidin-1-yl)ethyl)-2'-fluoro-6'-hydroxy-[1,1'-biphenyl]-4-sulfonamide
InChi Key
PDUWTNSNRYDIMZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H32F2N6O4S/c1-20(41)32-31(25-17-23(33)7-10-27(25)36-32)28-19-40(38-37-28)18-21-11-14-39(15-12-21)16-13-35-45(43,44)24-8-5-22(6-9-24)30-26(34)3-2-4-29(30)42/h2-10,17,19,21,35-36,42H,11-16,18H2,1H3
SMILES Code
O=S(C1=CC=C(C2=C(O)C=CC=C2F)C=C1)(NCCN3CCC(CN4N=NC(C5=C(C(C)=O)NC6=C5C=C(F)C=C6)=C4)CC3)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 634.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Marlhoux L, Arnaud A, Hervieu C, Makulyte G, Martinasso C, Mularoni A, Delcros JG, Krimm I, Hernandez-Vargas H, Ichim G, Meurette O, Neves D, Bancet A. Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination. J Med Chem. 2025 Jun 10. doi: 10.1021/acs.jmedchem.5c00695. Epub ahead of print. PMID: 40493957.

View History

YD2

YD2

Featured